KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Other Non-Current Liabilities (2016 - 2025)

Travere Therapeutics (TVTX) has disclosed Other Non-Current Liabilities for 14 consecutive years, with $7.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Other Non-Current Liabilities rose 11.85% year-over-year to $7.6 million, compared with a TTM value of $7.6 million through Dec 2025, up 11.85%, and an annual FY2025 reading of $7.6 million, up 11.85% over the prior year.
  • Other Non-Current Liabilities was $7.6 million for Q4 2025 at Travere Therapeutics, up from $5.9 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $76.2 million in Q3 2022 and bottomed at $5.9 million in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $23.2 million, with a median of $10.3 million recorded in 2023.
  • Peak annual rise in Other Non-Current Liabilities hit 626.57% in 2023, while the deepest fall reached 89.0% in 2023.
  • Year by year, Other Non-Current Liabilities stood at $67.1 million in 2021, then tumbled by 86.01% to $9.4 million in 2022, then rose by 9.96% to $10.3 million in 2023, then tumbled by 34.15% to $6.8 million in 2024, then rose by 11.85% to $7.6 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for TVTX at $7.6 million in Q4 2025, $5.9 million in Q3 2025, and $7.9 million in Q2 2025.